tiprankstipranks

BioMarin price target raised to $103 from $99 at BofA

BofA raised the firm’s price target on BioMarin (BMRN) to $103 from $99 and keeps a Buy rating on the shares following what the firm calls “solid top and bottom-line consensus beats.” The firm cites higher margins for its price target raise, adding that it sees an “undemanding valuation which ascribes minimal value to Voxzogo first-mover and franchise preservation strategies.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue